Cost–utility analysis of oral deferasirox versus infusional deferoxamine in transfusion‐dependent β‐thalassemia patients

Abstract

We conclude that the use of DFX instead of DFO represents a cost-effective use of resources for treatment of iron overload in patients with β-thalassemia from Iran's society perspective.